Bay­er dou­bles down on ra­dio­ther­a­py with ac­qui­si­tions of 2 tiny biotech play­ers built around re­search from Cor­nell

With #AS­CO21 just days away, Swiss drug­mak­er No­var­tis is set to un­veil late-stage da­ta for its high­ly tout­ed ra­di­oli­gand, po­ten­tial­ly chart­ing a new course for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER